Current report No. 3/2023 – Information regarding the Company’s meeting with the Food and Drug Administration (FDA) under the End of Phase II (EOP2) meeting procedure for Celon’s esketamine DPI (Falkieri) project
24 March 2023 | Current reports
Date: February 24, 2023, 10:44 AMLegal basis: Article 17 of the Market Abuse Regulation (MAR) – inside information. The Management Board of Celon Pharma S.A. (“Company”) hereby informs that on February 23, 2023, the so-called End of Phase II meeting took place. The participants included, among others, the Division of Psychiatry at the Food andRead more »
Welcome to Celon Pharma S.A.
Celon Pharma S.A. is an integrated pharmaceutical company which conducts advanced research and manufactures modern drugs. The company is also a successful marketing authorisation holder for it products. The drugs we offer help thousands of patients lead a better and longer life.
News
- Current report No. 3/2023 – Information regarding the Company’s meeting with the Food and Drug Administration (FDA) under the End of Phase II (EOP2) meeting procedure for Celon’s esketamine DPI (Falkieri) projectDate: February 24, 2023, 10:44 AMLegal basis: Article 17 of the Market Abuse Regulation (MAR) – inside information. The Management Board of Celon Pharma S.A. (“Company”) hereby informs that onRead more »
- Current report No. 2/2023Date prepared: 06/02/2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Receipt of a notification regarding a change in the total number of votes in the Company Legal basis:Read more »
- Current report No. 1/2023 – Dates for submitting periodic reports in 2023Date prepared: 25/01/2023 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Dates for submitting periodic reports in 2023 Legal basis: Article 56 subs. 1 point 2 of the ActRead more »
Research and development
We create innovative drugs, that will change the lives of patients globally
Products
We are leaders in
inhalation technology
